These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25989829)

  • 21. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching to an etravirine-containing regimen due to drug intolerance in clinical practice.
    Martín-Carbonero L; Moreno V; Ramírez-Olivenza G; Valencia E
    HIV Clin Trials; 2014; 15(2):57-61. PubMed ID: 24710919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
    Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
    HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
    Calin R; Paris L; Simon A; Peytavin G; Wirden M; Schneider L; Valantin MA; Tubiana R; Agher R; Katlama C
    Antivir Ther; 2012; 17(8):1601-4. PubMed ID: 22941896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
    Rahman AP; Eaton SA; Nguyen ST; Bain AM; Payne KD; Bedimo R; Busti AJ
    Pharmacotherapy; 2008 Jul; 28(7):913-9. PubMed ID: 18576906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).
    Rusconi S; Adorni F; Bruzzone B; Di Biagio A; Meini G; Callegaro A; Punzi G; Boeri E; Pecorari M; Monno L; Gianotti N; Butini L; Galli L; Polilli E; Galli M;
    Clin Microbiol Infect; 2013 Oct; 19(10):E443-6. PubMed ID: 23621421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
    Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
    Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
    Nguyen A; Calmy A; Delhumeau C; Mercier I; Cavassini M; Mello AF; Elzi L; Rauch A; Bernasconi E; Schmid P; Hirschel B
    AIDS; 2011 Jul; 25(12):1481-7. PubMed ID: 21593661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.